Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
Recruiting · NCT06249048 · Registry updated 2025-10-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm, triple-negative breast carcinoma | Recruiting | Phase 1 / Phase 2 | 2025-10-29 | NCT06249048 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Strand Therapeutics Inc. | 2 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cleveland Clinic | Cleveland | United States | 558 |
| HonorHealth Research and Innovation Institute | Scottsdale | United States | 7 |
| Huntsman Cancer Institute - University of Utah | Salt Lake City | United States | 7 |
| Melanoma Institute Australia | Wollstonecraft | Australia | 1 |
| NextGen Oncology | Beverly Hills | United States | 2 |
| The University of Texas MD Anderson Cancer Center | Houston | United States | 207 |
| University of Pittsburgh Medical Center | Pittsburgh | United States | 63 |